Industry Overview - The biopharmaceutical industry is experiencing challenges due to ongoing tariffs and drug pricing pressures from the Trump administration, leading to a 5.7% decline in the combined market capitalisation of the top 20 global biopharmaceutical companies, from $3.92 trillion on March 31, 2025, to $3.70 trillion on June 30, 2025 [1] Company Performances - Alnylam achieved the largest market capitalisation growth of 21.8%, reaching $42.5 billion, driven by strong sales of its RNA interference therapeutic Amvuttra, which saw a 59% year-on-year increase in global sales to $310 million in Q1 2025 [2] - Novartis reported a 7.7% increase in market capitalisation in Q2 2025, bolstered by strong sales of blockbuster drugs such as Entresto, Cosentyx, Kesimpta, and Kisqali, along with the acquisition of Regulus Therapeutics for $1.7 billion, enhancing its renal disease portfolio [3] - Bristol Myers Squibb experienced the largest decline in market capitalisation at 22.9% due to mixed Q1 2025 financial results and negative trial outcomes, particularly the failure of its Phase III ARISE trial for Cobenfy [4] - Regeneron and Sanofi saw market capitalisation declines of 18.7% and 13.8%, respectively, following the failure of their partnered drug itepekimab in the Phase III AERIFY-2 trial, which aimed to reduce exacerbations of chronic obstructive pulmonary disease [5]

As filed with the Securities and Exchange Commission on September 5, 2025. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER (Primary Standard Industrial Classification Code Number) Cayman Islands 8731 N/A (I.R.S. Employer Identification Number) THE SECURITIES ACT OF 1933 Silexion Therapeutics Corp (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) 12 Abba Hill ...

Company Overview - Alnylam Pharmaceuticals, Inc. is a leading player in the biopharmaceutical industry, focusing on RNA interference (RNAi) therapeutics aimed at silencing specific genes associated with various diseases [1] - The company competes with other biotech firms such as Moderna and BioNTech, positioning itself among the leaders in the sector [1] Recent Developments - On September 5, 2025, Kostas Biliouris from BMO Capital set a price target of $470 for ALNY, indicating a potential upside of about 3.8% from its trading price of $452.81 at that time [2] - Alnylam participated in Citi's Biopharma Back to School Conference on September 3, 2025, where key executives discussed the company's strategic initiatives and future plans [3] Stock Performance - Currently, ALNY's stock is priced at $452.13, reflecting a slight decrease of 0.31% or $1.41, with a daily trading range between $444.66 and $455.05 [4] - Over the past year, ALNY has experienced significant volatility, with a high of $469.81 and a low of $205.87 [4] Market Position - Alnylam's market capitalization is approximately $59.26 billion, indicating a substantial presence in the market [5] - The stock has a trading volume of 264,290 shares on the NASDAQ exchange, highlighting active trading and investor interest in Alnylam's growth potential [5]

Core Insights - Silexion Therapeutics Corp. is a clinical-stage biotechnology company focused on RNA interference therapies for KRAS-driven cancers [1][3] - The company will present at the 27th Annual H.C. Wainwright Global Investment Conference on September 10, 2025 [1][2] - Silexion's lead product candidate targets locally advanced pancreatic cancer and has shown positive trends in a Phase 2a clinical trial compared to chemotherapy alone [3] Company Presentation Details - The presentation is scheduled for September 10, 2025, at 2:00 PM ET [2] - An updated company presentation is available on Silexion's investor website [2] - Management will be available for one-on-one investor meetings during the conference [2] Company Background - Silexion Therapeutics is dedicated to developing innovative treatments for solid tumor cancers with mutated KRAS oncogenes, which are prevalent in human cancers [3] - The company aims to advance therapeutic options in oncology, particularly for patients with unsatisfactorily treated cancers [3]

As filed with the Securities and Exchange Commission on August 26, 2025. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Silexion Therapeutics Corp (Exact name of registrant as specified in its charter) Cayman Islands 8731 N/A (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Code Number) (I.R.S. Employer Identification Number) 12 Abba Hillel ...

Core Insights - Silexion Therapeutics Corp. announced positive preclinical data for SIL204, demonstrating significant efficacy in human lung cancer cell lines, particularly those with KRAS G12D mutations [1][4][6] - The company is conducting a new study on an untested KRAS mutation, with results expected soon, which could further validate SIL204 as a potential pan-KRAS treatment [2][3] - Silexion's dual-route administration strategy is progressing, with plans to initiate a Phase 2/3 clinical trial in Q2 2026 for KRAS-driven solid tumors [3] Study Findings - The study showed dose-dependent inhibition in lung cancer cells with KRAS G12D mutations, highlighting SIL204's potential as a versatile therapeutic [4][7] - The lipid-conjugated delivery system enhances SIL204's entry into tumor cells, addressing a significant barrier for siRNA technology [5][6] Market Opportunity - KRAS mutations are prevalent in various cancers, with approximately 90% in pancreatic cancers, 45% in colorectal cancers, and 30% in lung cancers, representing a significant market opportunity [8] - The global treatment market for these cancers exceeds US $30 billion annually, with many KRAS variants challenging to target with conventional therapies, underscoring the potential of Silexion's RNAi-based strategy [8][9] Company Overview - Silexion Therapeutics is focused on developing RNA interference therapies for solid tumors driven by KRAS mutations, with SIL204 as its next-generation candidate showing promise in preclinical studies [10]

Core Insights - Instil Bio, Inc. has appointed John Maraganore, Ph.D., to the Board of Directors of its subsidiary Axion Bio, Inc., which is focused on developing AXN-2510, a PD-L1xVEGF bispecific antibody targeting solid tumors, particularly non-small cell lung cancer (NSCLC) [1][2] - The appointment is aimed at enhancing leadership to maximize the value of the AXN-2510 program for both patients and shareholders, with expectations of redefining the standard of care for solid tumors [2] - AXN-2510 is currently in a Phase 2 trial in combination with chemotherapy for first-line NSCLC, with early signs of safety and efficacy being reported [2] Company Overview - Instil Bio is a clinical-stage biopharmaceutical company dedicated to developing novel therapies, with AXN-2510 as its lead asset [3] - Axion Bio, a wholly-owned subsidiary of Instil Bio, is specifically focused on the development of AXN-2510 for multiple solid tumors [4] Leadership Background - Dr. John Maraganore brings over 30 years of biotechnology experience, having previously served as the founding CEO of Alnylam Pharmaceuticals, where he led the company to a market capitalization exceeding $40 billion [2] - His expertise spans drug discovery, clinical development, and strategic partnerships, making him a valuable asset for guiding the advancement of next-generation cancer therapies [2]

Core Insights - Silexion Therapeutics has demonstrated the efficacy of its RNAi therapeutic candidate, SIL204, against KRAS-driven cancers, showing a significant inhibition rate of approximately 90% in GP2D human colorectal cancer cells [1][5] - The company plans to conduct further preclinical studies focusing on lung cancer cell lines to expand the understanding of SIL204's therapeutic potential [2][4] Company Overview - Silexion Therapeutics is a clinical-stage biotechnology company specializing in RNA interference therapies targeting KRAS mutations, which are prevalent in various cancers [6] - The company’s first-generation product, LODER™, has shown promising results in Phase 2 trials for non-resectable pancreatic cancer, while SIL204 aims to target a broader range of KRAS mutations [6] Therapeutic Potential - SIL204 has shown significant inhibition of cancer cell proliferation and metabolic activity across multiple cancer types, including pancreatic, colorectal, and lung cancers, indicating its potential as a pan-KRAS therapy [4][5] - KRAS mutations are found in approximately 90% of pancreatic cancers, 45% of colorectal cancers, and 35% of non-squamous non-small-cell lung cancers, representing a substantial market opportunity exceeding US $30 billion annually [4][6]

Company Overview - TransCode Therapeutics, Inc. is a clinical-stage oncology company focused on developing RNA-targeted therapeutics for cancer treatment [1][4] - The company aims to combat metastatic disease through the intelligent design and effective delivery of RNA therapeutics using its proprietary TTX nanoparticle platform [4] Key Appointment - Dr. Phillip D. Zamore has been appointed to the Scientific Advisory Board of TransCode Therapeutics [1] - Dr. Zamore is recognized for his pioneering work in RNA interference (RNAi) and co-founded Alnylam Pharmaceuticals, which developed the first FDA-approved RNAi drug [1][6] Research Contributions - Dr. Zamore's research has advanced the understanding of non-coding RNA and its implications in health and disease, particularly in the processing of microRNAs [2] - His contributions have earned him recognition from prestigious institutions, including the National Academy of Sciences and the National Academy of Medicine [2] Strategic Vision - The company emphasizes the importance of Dr. Zamore's expertise in RNA biology to enhance its pipeline of RNA-targeted cancer therapies [3] - Dr. Zamore expressed enthusiasm for contributing to the development of effective RNA-based treatments for cancer patients [3] Product Focus - TransCode's lead therapeutic candidate, TTX-MC138, targets metastatic tumors that overexpress microRNA-10b, a biomarker associated with metastasis [4] - The company has a portfolio of first-in-class RNA therapeutic candidates aimed at overcoming RNA delivery challenges to access novel genetic targets for various cancers [4]

Core Insights - Biogen and City Therapeutics have announced a strategic collaboration to develop novel RNA interference (RNAi) therapies, combining Biogen's drug development expertise with City Therapeutics' RNAi engineering technologies [1][2][3] - The collaboration will initially focus on a target related to central nervous system diseases, utilizing advanced drug delivery technologies for systemic administration [2][3] - City Therapeutics will receive $46 million, including a $16 million upfront payment and a $30 million investment, with potential milestone payments of up to $1 billion based on development success [3] Company Overview - Biogen is a leading biotechnology company founded in 1978, focused on innovative science to deliver new medicines and create shareholder value [4] - City Therapeutics is a biopharmaceutical company specializing in next-generation RNAi technologies, aiming to expand the therapeutic reach of RNAi-based medicines [6]